Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Characterization of mesenchymal stem cells under the stimulation of Toll-like receptor agonists.

Chen X, Zhang ZY, Zhou H, Zhou GW.

Dev Growth Differ. 2014 Apr;56(3):233-44. doi: 10.1111/dgd.12124.

PMID:
24645700
2.

Expression and role of Toll-like receptors on human umbilical cord mesenchymal stromal cells.

Chen D, Ma F, Xu S, Yang S, Chen F, Rong L, Chi Y, Zhao Q, Lu S, Han Z, Pang A, Han Z.

Cytotherapy. 2013 Apr;15(4):423-33. doi: 10.1016/j.jcyt.2012.12.001.

PMID:
23352460
3.

The role of Toll-like receptor 3 and 4 in regulating the function of mesenchymal stem cells isolated from umbilical cord.

Zhang L, Liu D, Pu D, Wang Y, Li L, He Y, Li Y, Li L, Qiu Z, Zhao S, Li W.

Int J Mol Med. 2015 Apr;35(4):1003-10. doi: 10.3892/ijmm.2015.2106.

PMID:
25695694
4.

Toll like receptor 3 & 4 responses of human turbinate derived mesenchymal stem cells: stimulation by double stranded RNA and lipopolysaccharide.

Hwang SH, Cho HK, Park SH, Lee W, Lee HJ, Lee DC, Oh JH, Park SH, Kim TG, Sohn HJ, Kang JM, Kim SW.

PLoS One. 2014 Jul 8;9(7):e101558. doi: 10.1371/journal.pone.0101558.

5.

Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling.

Liotta F, Angeli R, Cosmi L, Filì L, Manuelli C, Frosali F, Mazzinghi B, Maggi L, Pasini A, Lisi V, Santarlasci V, Consoloni L, Angelotti ML, Romagnani P, Parronchi P, Krampera M, Maggi E, Romagnani S, Annunziato F.

Stem Cells. 2008 Jan;26(1):279-89.

6.

Immunomodulatory properties of mesenchymal stem cells derived from dental pulp and dental follicle are susceptible to activation by toll-like receptor agonists.

Tomic S, Djokic J, Vasilijic S, Vucevic D, Todorovic V, Supic G, Colic M.

Stem Cells Dev. 2011 Apr;20(4):695-708. doi: 10.1089/scd.2010.0145.

PMID:
20731536
7.

Priming of Toll-like receptor 4 pathway in mesenchymal stem cells increases expression of B cell activating factor.

Yan H, Wu M, Yuan Y, Wang ZZ, Jiang H, Chen T.

Biochem Biophys Res Commun. 2014 May 30;448(2):212-7. doi: 10.1016/j.bbrc.2014.04.097.

8.
9.

The expression and role of miR-301a in human umbilical cord-derived mesenchymal stromal cells.

Ma F, Chen D, Chi Y, Chen F, Li X, Han Z.

Cytotherapy. 2013 Dec;15(12):1511-6. doi: 10.1016/j.jcyt.2013.06.007.

PMID:
24035358
10.

Stimulation of mesenchymal stromal cells (MSCs) via TLR3 reveals a novel mechanism of autocrine priming.

Dumitru CA, Hemeda H, Jakob M, Lang S, Brandau S.

FASEB J. 2014 Sep;28(9):3856-66. doi: 10.1096/fj.14-250159.

11.

Toll-like receptor 3 pre-conditioning increases the therapeutic efficacy of umbilical cord mesenchymal stromal cells in a dextran sulfate sodium-induced colitis model.

Fuenzalida P, Kurte M, Fernández-O'ryan C, Ibañez C, Gauthier-Abeliuk M, Vega-Letter AM, Gonzalez P, Irarrázabal C, Quezada N, Figueroa F, Carrión F.

Cytotherapy. 2016 May;18(5):630-41. doi: 10.1016/j.jcyt.2016.02.002.

PMID:
27059200
12.

Tonsil-derived mesenchymal stromal cells produce CXCR2-binding chemokines and acquire follicular dendritic cell-like phenotypes under TLR3 stimulation.

Ryu JH, Park M, Kim BK, Ryu KH, Woo SY.

Cytokine. 2015 Jun;73(2):225-35. doi: 10.1016/j.cyto.2015.02.028.

PMID:
25794662
13.

Toll-like receptors 2 and 4 mediate the capacity of mesenchymal stromal cells to support the proliferation and differentiation of CD34⁺ cells.

Wang X, Cheng Q, Li L, Wang J, Xia L, Xu X, Sun Z.

Exp Cell Res. 2012 Feb 1;318(3):196-206. doi: 10.1016/j.yexcr.2011.11.001.

PMID:
22100911
14.

Prolonged exposure to bacterial toxins downregulated expression of toll-like receptors in mesenchymal stromal cell-derived osteoprogenitors.

Mo IF, Yip KH, Chan WK, Law HK, Lau YL, Chan GC.

BMC Cell Biol. 2008 Sep 18;9:52. doi: 10.1186/1471-2121-9-52.

15.

Lipopolysaccharides can protect mesenchymal stem cells (MSCs) from oxidative stress-induced apoptosis and enhance proliferation of MSCs via Toll-like receptor(TLR)-4 and PI3K/Akt.

Wang ZJ, Zhang FM, Wang LS, Yao YW, Zhao Q, Gao X.

Cell Biol Int. 2009 Jun;33(6):665-74. doi: 10.1016/j.cellbi.2009.03.006.

PMID:
19376254
16.

IL-29 enhances Toll-like receptor-mediated IL-6 and IL-8 production by the synovial fibroblasts from rheumatoid arthritis patients.

Xu L, Feng X, Tan W, Gu W, Guo D, Zhang M, Wang F.

Arthritis Res Ther. 2013 Oct 29;15(5):R170. doi: 10.1186/ar4357.

17.

TLR3-/4-Priming Differentially Promotes Ca(2+) Signaling and Cytokine Expression and Ca(2+)-Dependently Augments Cytokine Release in hMSCs.

Park KS, Kim SH, Das A, Yang SN, Jung KH, Kim MK, Berggren PO, Lee Y, Chai JC, Kim HJ, Chai YG.

Sci Rep. 2016 Mar 16;6:23103. doi: 10.1038/srep23103.

18.

Mesenchymal stem cell therapy for cardiac inflammation: immunomodulatory properties and the influence of toll-like receptors.

van den Akker F, de Jager SC, Sluijter JP.

Mediators Inflamm. 2013;2013:181020. doi: 10.1155/2013/181020. Review.

19.

Toll-like receptor-induced innate immune responses in non-parenchymal liver cells are cell type-specific.

Wu J, Meng Z, Jiang M, Zhang E, Trippler M, Broering R, Bucchi A, Krux F, Dittmer U, Yang D, Roggendorf M, Gerken G, Lu M, Schlaak JF.

Immunology. 2010 Mar;129(3):363-74. doi: 10.1111/j.1365-2567.2009.03179.x.

20.

Inflammation and Toll-like receptor ligation differentially affect the osteogenic potential of human mesenchymal stromal cells depending on their tissue origin.

Raicevic G, Najar M, Pieters K, De Bruyn C, Meuleman N, Bron D, Toungouz M, Lagneaux L.

Tissue Eng Part A. 2012 Jul;18(13-14):1410-8. doi: 10.1089/ten.TEA.2011.0434.

PMID:
22429150
Items per page

Supplemental Content

Support Center